Recipharm AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – GlobalData’s summarization of the company’s business strategy.
SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, development and technology services. The company's manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, oral liquids, solid doses, and sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services assist customers from the initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, and validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel, and the US. Recipharm is headquartered in Stockholm, Sweden.
Recipharm AB Key Recent Developments
Apr 04,2023: Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer Mar 09,2023: Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand Nov 30,2022: Recipharm invests in its single dose nasal platform capabilities Oct 25,2022: Recipharm bolsters blow-fill-seal capabilities with Lab+
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.
Section 1 - About the Company
Recipharm AB - Key Facts
Recipharm AB - Key Employees
Recipharm AB - Key Employee Biographies
Recipharm AB - Major Products and Services
Recipharm AB - History
Recipharm AB - Company Statement
Recipharm AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB - Business Description
Recipharm AB - Corporate Strategy
Recipharm AB - SWOT Analysis
SWOT Analysis - Overview
Recipharm AB - Strengths
Recipharm AB - Weaknesses
Recipharm AB - Opportunities
Recipharm AB - Threats
Recipharm AB - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Recipharm AB, Recent Deals Summary
Section 4 – Company’s Recent Developments
Apr 04, 2023: Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer
Mar 09, 2023: Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand
Nov 30, 2022: Recipharm invests in its single dose nasal platform capabilities
Oct 25, 2022: Recipharm bolsters blow-fill-seal capabilities with Lab+
Oct 19, 2022: Recipharm strengthens pre-filled syringe and cartridge offering with new investment
Jul 14, 2022: Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
Apr 29, 2022: Recipharm offers services to enable switch to next generation pMDI propellants
Feb 23, 2022: Recipharm invests in new high-speed filling line to meet demand for aseptic products
Jan 28, 2022: Recipharm: Construction works launch at new fill finish facility in Morocco
Jan 27, 2022: Recipharm secures vaccine manufacturing deal
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Recipharm AB, Recent Deals Summary
List of Figures
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023